FDA's Advisory Meetings(8月29日)
公開日時 2011/08/31 04:00
Recent And Upcoming FDA Advisory Committee Meetings |
Topic |
Advisory Committee |
Date |
Bitmap FDA's draft Strategic Plan for Regulatory Science; FDA's Medical Countermeasures Initiative program plans |
Science Board |
Aug. 19 |
Johnson & Johnson's Xarelto (rivaroxaban) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation |
Cardiovascular and Renal Drugs |
Sept. 8 |
Benefits and risks of long-term use of bisphosphonates such as Merck's Fosamax (alendronate), Warner Chilcott's Actonel/Atelvia (risedronate), Roche's Boniva (ibandronate) and Novartis' Reclast (zoledronic acid) for osteoporosis, given safety concerns about osteonecrosis of the jaw and atypical femur fractures |
Reproductive Health Drugs and Drug Safety and Risk Management |
Sept. 9 |
ApoPharma/Cato Research's Ferriprox (deferiprone) for treatment of transfusional iron overload with inadequate chelation; trial designs and endpoints for products to treat patients with non-metastatic castration-resistant prostate cancer who have a rising serum level of prostate-specific antigen despite being on androgen deprivation therapy |
Oncologic Drugs |
Sept. 14 |
Surrogate endpoint (safety and immunogenicity) for Pfizer's Prevnar 13 pneumococcal conjugate vaccine in patients over age 50 under accelerated approval; overview of FDA's Laboratory of Enteric and Sexually Transmitted Diseases research program |
Vaccines and Related Biological Products |
Sept. 20 |
Pediatric-focused safety reviews under BPCA and PREA for various drugs; informational update on pediatric use of Abbott's HIV treatment Kaletra (lopinavir/ritonavir) |
Pediatric |
Sept. 22-23 |
Teva Neuroscience's Azilect (rasagiline) for idiopathic Parkinson's disease to slow clinical progression and treat signs and symptoms as initial monotherapy and as adjunct therapy to levodopa |
Peripheral and Central Nervous System Drugs |
Oct. 17 |
(The Pink Sheet 8月22日号より) FDAと米国製薬企業の情報満載 “The Pink Sheet”はこちらから